ImaginAb Announces New Supply Agreement to Supply Genmab A/S with its Investigational CD8 ImmunoPET Agent

Los Angeles, CA, USA, May 5th, 2022 – ImaginAb, Inc., a market leading global biotechnology company focused on developing next generation ImmunoPET imaging agents and therapeutic radiopharmaceuticals (RPT), is pleased to announce it has signed a new multi-year, non-exclusive supply agreement with Genmab A/S, an international biotechnology company.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH